Status:
COMPLETED
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
Lead Sponsor:
Sonexa Therapeutics, Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 ...
Detailed Description
Alzheimer's disease (AD) is a progressive and fatal neurological illness. It produces changes in the brain that include loss of cells and accumulation of abnormal protein deposits. Initial symptoms ar...
Eligibility Criteria
Inclusion
- Diagnostic evidence of mild to moderate Alzheimer's disease.
- CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.
- A reliable and capable caregiver.
Exclusion
- Subjects who reside in a skilled nursing facility.
- Subjects with B12 or folate deficiency.
- Subjects with chronic hepatic disease.
- Subjects with a recent history of hematologic/oncologic disorders.
- Subjects who have experienced a myocardial infarction with the past year.
- Dementia caused or complicated by other organic disease
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT00842673
Start Date
February 1 2009
End Date
September 1 2010
Last Update
June 7 2012
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Costa Mesa, California, United States
2
Redlands, California, United States
3
San Diego, California, United States
4
Walnut Creek, California, United States